Forging New Paths for the Digital Revolution in Healthcare
The past two decades have witnessed transformative changes in our approach to using modeling & simulation to assess and manage drug–drug interactions (DDIs). Multidisciplinary innovations in mechanistic assessment of absorption, distribution, metabolism, and excretion (ADME), population pharmacology and pharmacogenomics, physiologically based modeling, and regulatory science have enabled a profound shift in mindset from risk aversion to informative prescribing guidance for optimal risk management1 . These advances have resulted in a sea change in how we study and regulate DDIs, as documented in two newly published FDA guidance documents.
© 2021 SOURCE EXPLORER® All rights reserved